Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines

Experimental Hematology

Volumn 40, Issue 10, 2012, Pages 800-810

  Valdez, Benigno C ^a   Nieto, Yago ^a   Murray, David ^b   Li, Yang ^a   Wang, Guiyun ^a   Champlin, Richard E ^a   Andersson, Borje S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIGEN; BUSULFAN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; GEMCITABINE; KRAB ASSOCIATED PROTEIN 1; MELPHALAN; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL KILLING; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INDUCTION; EPIGENETICS; EXPOSURE; FLOW CYTOMETRY; GROWTH INHIBITION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TUMOR CELL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, ALKYLATING; AZACITIDINE; BUSULFAN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXINS; DEOXYCYTIDINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EPIGENESIS, GENETIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA; MELPHALAN; PROTEIN-SERINE-THREONINE KINASES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 84866338504     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.06.001     Document Type: Article

References (46)

1. Murawski N., Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 2010, 11:1074-1085.
2. Klyuchnikov E., Bacher U., Kröger N., et al. The role of allogeneic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma patients. Adv Hematol 2011, 2011:974658.
3. Salit R.B., Bishop M.R., Pavletic S.Z. Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma?. Curr Hematol Malig Rep 2010, 5:229-238.
4. Srivastava S., Jones D., Wood L.L., et al. A Phase I Trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2011, 17:987-994.
5. Suyani E., Sucak G.T., Aki S.Z., Yeĝin Z.A., Ozkurt Z.N., Yaĝci M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 2011, 90:685-691.
6. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
7. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
8. Andersson B.S., de Lima M., Thall P.F., et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 4:672-684.
9. Haddow A., Timmis G.M. Myleran in chronic myeloid leukaemia; chemical constitution and biological action. Lancet 1953, 264:207-208.
10. Knock F.E. Newer anticancer agents. Med Clin North Am 1964, 48:501-527.
11. Hanada K., Budzowska M., Modesti M., et al. The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. EMBO J 2006, 25:4921-4932.
12. Plunkett W., Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif 2001, 19:21-45.
13. Parker W.B., Shaddix S.C., Chang C.H., et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res 1991, 51:2386-2394.
14. Yamauchi T., Nowak B.J., Keating M.J., Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001, 11:3580-3589.
15. Valdez B.C., Li Y., Murray D., Champlin R.E., Andersson B.S. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol 2011, 81:222-232.
16. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
17. Valdez B.C., Andersson B.S. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen 2010, 51:659-668.
18. Valdez B.C., Murray D., Nieto Y., Li Y., Wang G., Champlin R.E., Andersson B.S. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and SAHA in lymphoma cell lines. Leuk Lymphoma 2012, 53:973-981.
19. Valdez B.C., Murray D., Ramdas L., et al. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 2008, 32:1684-1697.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
21. Hassan Z., Hassan M., Hellström-Lindberg E. The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro. Leukemia 2001, 15:1240-1247.
22. Bosanquet A.G., Bird M.C. Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays. Cancer Chemother Pharmacol 1988, 21:211-215.
23. Martin S.J., Reutelingsperger C.P., McGahon A.J., et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995, 182:1545-1556.
24. Habib M., Fares F., Bourgeois C.A., et al. DNA global hypomethylation in EBV-transformed interphase nuclei. Exp Cell Res 1999, 249:46-53.
25. Drabløs F., Feyzi E., Aas P.A., et al. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst) 2004, 3:1389-1407.
26. Ewald B., Sampath D., Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008, 27:6522-6537.
27. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273:5858-5868.
28. Kastan M.B., Lim D.S. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000, 1:179-186.
29. Bassing C.H., Alt F.W. H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity. Cell Cycle 2004, 3:149-153.
30. Ziv Y., Bielopolski D., Galanty Y., et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat Cell Biol 2006, 8:870-876.
31. Cimprich K.A., Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008, 9:616-627.
32. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. 2001;21:4129-4139.
33. Dubrez-Daloz L., Dupoux A., Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 2008, 7:1036-1046.
34. Lu X., Liu J., Legerski R.J. Cyclin E is stabilized in response to replication fork barriers leading to prolonged S phase arrest. J Biol Chem 2009, 284:35325-35337.
35. Rouleau M., Aubin R.A., Poirier G.G. Poly(ADP-ribosyl)ated chromatin domains: access granted. J Cell Science 2004, 117:815-825.
36. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
37. Scognamiglio A., Nebbioso A., Manzo F., Valente S., Mai A., Altucci L. HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta 2008, 1783:2030-2038.
38. Vaute O., Nicolas E., Vandel L., Trouche D. Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res 2002, 30:475-481.
39. Wade P.A., Gegonne A., Jones P.L., Ballestar E., Aubry F., Wolffe A.P. Mi-2 complex couples DNA methylation to chromatin remodeling and histone deacetylation. Nat Gen 1999, 23:62-66.
40. Feng Q., Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev 2001, 15:827-832.
41. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
42. Conti C., Leo E., Eichler G.S., et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 2010, 70:4470-4480.
43. Aguilera A., Gomez-Gonzalez B. Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet 2008, 9:204-217.
44. Cerqueira N.M., Fernandes P.A., Ramos M.J. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry 2007, 13:8507-8515.
45. Choudhary C., Kumar C., Gnad F., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
46. Goodarzi A.A., Noon A.T., Deckbar D., et al. ATM signaling facilitates repair of DNA double-strand breaks associated with heterochromatin. Mol Cell 2008, 31:167-177.